低分子肝素钠早期干预治疗FGR的临床研究

Clinical study of low molecular weight heparin in early intervention and therapy of FGR

目的：探讨低分子肝素钠早期干预治疗胎儿生长受限的临床效果及对围生儿结局的影响。方法选取我院2009年1月～2014年1月收治的经产前检查诊断为胎儿生长受限的孕妇200例，分为观察组和对照组，每组100例。两组患者在治疗母体基础性疾病基础上，观察组早期进行低分子肝素钠治疗，对照组单纯为加强饮食营养。观察两组孕妇每周宫高和腹围、胎儿双顶径、头围、股骨长。结果观察组明显优于对照组，差异具有统计学意义（P＜0.05）；两组患者胎儿治疗前的羊水、生物物理评分以及S/D评分比较，无显著性差异（P＞0.05），治疗后观察组明显的优于对照组，差异具有统计学意义（P＜0.05）；两组患者新生儿胎龄、体重以及窒息情况比较，差异均有显著性（P＜0.05）。结论低分子肝素钠在改善胎盘循环，促进胎儿生长发育方面临床效果肯定，且对母亲和胎儿安全性均较好。

Objective To study the clinical effect of low molecular weight heparin in early intervention and therapy of fetal growth restriction （FGR） and the effect of perinatal fetus outcome. Methods 200 pregnant women who were diagnosed as FGR prenatal examination in our hospital from January 2009 to January 2014 were divided into treatment group and control group, with 100 cases in each group. Based on the treatment of maternal basic diseases of the two groups, treatment group was early treated by low molecular weight heparin, while control group was simply strengthened with diet nutrition. To observe weekly the uterine height, the abdominal circumference, the fetal biparietal diameter, the head circumference, and the femur length of the two groups. Results The treatment group was was significantly higher than the control group, the difference had statistical significance（P 〈 0.05）. The amniotic fluid, the biophysical score, and the S/D score was no significant difference before treatment of ailing fetus between the two groups（P 〉 0.05）, while which were higher after treatment in treatment group than in control group, the difference was significant between the two groups（P 〈 0.05）. The fetal age, the body weight, and the situation of asphyxia of newborns between the two groups had significant difference （P〈0.05）. Conclusion The clinical effect of low molecular weight heparin in the improvement of placental circulation and the promotion of the fetal growth is affirmative, and the safety of which in mothers and fetus is better.